1. PROSPER: trial design
                                                                                                                                                                
Shepherd J et al. Lancet. 2002;360:

2. PROSPER: Baseline Clinical Characteristics
Placebo
Pravastatin
Age (yrs)
75.3
75.4
Female (%) 52
History of any vascular disease, n (%)
1259 (43.2)
1306 (45.2)
Current smoker, n (%)
805 (27.6)
753 (26.0)
History of hypertension, n (%)
1793 (61.6)
1799 (62.2)
Mean SBP/DBP (mm Hg)
154.6/83.94
154.7/83.64
History of diabetes, n (%)
320 (11.0)
303 (10.5)
Shepherd J et al. Lancet. 2002;360:

3. PROSPER: Baseline Lipid Profile
Placebo
Pravastatin
Total cholesterol (mg/dL)
221
HDL-C (mg/dL) 50
LDL-C (mg/dL)
147
Triglycerides (mg/dL)
133
Shepherd J et al. Lancet. 2002;360:

4. PROSPER: primary endpoint (coronary death, nonfatal MI, and stroke).
                                                                                                                                                                
Shepherd J et al. Lancet. 2002;360:

5. PROSPER: rates of CHD-related death and nonfatal MI
                                                                                                                                                                
Shepherd J et al. Lancet. 2002;360:

6. PROSPER: rate of CHD-related death
                                                                                                                                                                
Shepherd J et al. Lancet. 2002;360:

7. PROSPER: rates of fatal and nonfatal stroke
                                                                                                                                                                
Shepherd J et al. Lancet. 2002;360: